Lovelace Biomedical has launched operations as a preclinical contract research organization (CRO), offering toxicology, pharmacology and other services to pharmaceutical and biotechnology companies. Preclinical services and expertise span the fields of respiratory disease, infectious disease, gene therapy, neuroscience, alternative tobacco products and medical countermeasures, as well as drug discovery.

Lovelace Biomedical draws on nearly seven decades of leadership in scientific research experience from the Lovelace family of companies, including the Lovelace Respiratory Research Institute, to utilize a multi-disciplinary toolset to address simple and complex preclinical challenges. Lovelace Biomedical’s services include toxicology, IND-enabling programs, formulation, pharmacology, bioanalytical/analytical chemistry and medicinal chemistry.

“The Lovelace family of companies has a rich history in scientific innovation from pioneering aviation medicine and work with NASA, to groundbreaking research in respiratory illnesses and infectious diseases,” said Robert Rubin, president and chief executive officer, Lovelace Respiratory Research Institute and associated companies. “Today we carry this tradition of scientific excellence through our collaborations with biotechnology and pharmaceutical companies that seek to improve lives by treating devastating diseases and disorders. Our expertise in preclinical research can help these companies answer difficult questions about their therapeutic programs and find the right path forward toward clinical investigation and regulatory approval.”

Operating in an expansive bio-secure facility on 100 acres of land with 300,000 square feet of laboratory space, Lovelace Biomedical says it is capable of handling preclinical activities for nearly any therapeutic program.